FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2113679439> ?p ?o ?g. }

• W2113679439 endingPage "994" @default.
• W2113679439 startingPage "985" @default.
• W2113679439 abstract "Various sebum free fatty acids (FFAs) have shown antibacterial activity against a broad range of Gram-positive bacteria, resulting in the suggestion that they are accountable, at least partially, for the direct antimicrobial activity of the skin surface. In this study, we examined the effects of sebum FFAs on the antimicrobial peptide (AMP)-mediated innate immune defense of human sebocytes. Incubation of lauric acid, palmitic acid, or oleic acid (OA) with human sebocytes dramatically enhanced their expression of human β-defensin (hBD)-2, one of the predominant AMPs found in the skin, whereas remarkable increases in hBD-1, hBD-3, and human cathelicidin LL-37 were not observed. Secreted hBD-2 was detectable by western blotting in the supernatant of sebocyte culture incubated with each FFA, but not with a vehicle control. The supernatant of FFA-incubated sebocyte culture showed antimicrobial activity against Propionibacterium acnes, whereas the enhanced antimicrobial activity of human sebocytes was neutralized by anti-hBD-2 IgG. In addition, the FFA-induced hBD-2 expression was suppressed by blocking the cluster of differentiation (CD)36 fatty acid translocase on the surface of sebocytes with anti-human CD36 IgG or blocking the NF-κB signaling pathway with BMS-345541, a highly selective inhibitor of inhibitory κB kinase. These data suggest that sebum FFAs upregulate the expression of hBD-2 in human sebocytes, which may enhance the disinfecting activity of the human sebaceous gland. The FFA-induced upregulation of hBD-2 is facilitated by CD36-mediated FFA uptake and NF-κB-mediated transactivation. The upregulation of mouse β-defensin 4, a mouse ortholog for hBD-2, was also observed in the hair follicle sebaceous glands of mouse ear skin after an epicutaneous application of OA, the most hBD-2-inducible FFA tested. This report highlights the potential of using FFAs as a multifunctional antimicrobial therapy agent for acne vulgaris treatment; FFAs may provide direct antibacterial activities against P. acnes and enhance the skin's innate antibacterial defense by inducing the expression of hBD-2 in sebocytes as well. Various sebum free fatty acids (FFAs) have shown antibacterial activity against a broad range of Gram-positive bacteria, resulting in the suggestion that they are accountable, at least partially, for the direct antimicrobial activity of the skin surface. In this study, we examined the effects of sebum FFAs on the antimicrobial peptide (AMP)-mediated innate immune defense of human sebocytes. Incubation of lauric acid, palmitic acid, or oleic acid (OA) with human sebocytes dramatically enhanced their expression of human β-defensin (hBD)-2, one of the predominant AMPs found in the skin, whereas remarkable increases in hBD-1, hBD-3, and human cathelicidin LL-37 were not observed. Secreted hBD-2 was detectable by western blotting in the supernatant of sebocyte culture incubated with each FFA, but not with a vehicle control. The supernatant of FFA-incubated sebocyte culture showed antimicrobial activity against Propionibacterium acnes, whereas the enhanced antimicrobial activity of human sebocytes was neutralized by anti-hBD-2 IgG. In addition, the FFA-induced hBD-2 expression was suppressed by blocking the cluster of differentiation (CD)36 fatty acid translocase on the surface of sebocytes with anti-human CD36 IgG or blocking the NF-κB signaling pathway with BMS-345541, a highly selective inhibitor of inhibitory κB kinase. These data suggest that sebum FFAs upregulate the expression of hBD-2 in human sebocytes, which may enhance the disinfecting activity of the human sebaceous gland. The FFA-induced upregulation of hBD-2 is facilitated by CD36-mediated FFA uptake and NF-κB-mediated transactivation. The upregulation of mouse β-defensin 4, a mouse ortholog for hBD-2, was also observed in the hair follicle sebaceous glands of mouse ear skin after an epicutaneous application of OA, the most hBD-2-inducible FFA tested. This report highlights the potential of using FFAs as a multifunctional antimicrobial therapy agent for acne vulgaris treatment; FFAs may provide direct antibacterial activities against P. acnes and enhance the skin's innate antibacterial defense by inducing the expression of hBD-2 in sebocytes as well. antimicrobial peptide cluster of differentiation colony-forming unit fetal bovine serum free fatty acid glyceraldehyde-3-phosphate dehydrogenase human β-defensin inhibitory κB kinase lauric acid mouse β-defensin-4 oleic acid palmitic acid phosphate-buffered saline" @default.
• W2113679439 created "2016-06-24" @default.
• W2113679439 creator A5007042386 @default.
• W2113679439 creator A5040150010 @default.
• W2113679439 creator A5041604568 @default.
• W2113679439 creator A5042304008 @default.
• W2113679439 creator A5057337678 @default.
• W2113679439 creator A5083005519 @default.
• W2113679439 date "2010-04-01" @default.
• W2113679439 modified "2023-10-15" @default.
• W2113679439 title "Sebum Free Fatty Acids Enhance the Innate Immune Defense of Human Sebocytes by Upregulating β-Defensin-2 Expression" @default.
• W2113679439 cites W1493113567 @default.
• W2113679439 cites W1534551308 @default.
• W2113679439 cites W1549363665 @default.
• W2113679439 cites W1571292455 @default.
• W2113679439 cites W1657392119 @default.
• W2113679439 cites W1691029863 @default.
• W2113679439 cites W1964758221 @default.
• W2113679439 cites W1965004275 @default.
• W2113679439 cites W1970038086 @default.
• W2113679439 cites W1981927278 @default.
• W2113679439 cites W1981956598 @default.
• W2113679439 cites W1985770391 @default.
• W2113679439 cites W1986453436 @default.
• W2113679439 cites W1987757002 @default.
• W2113679439 cites W1989234621 @default.
• W2113679439 cites W1990251709 @default.
• W2113679439 cites W2008054708 @default.
• W2113679439 cites W2008568914 @default.
• W2113679439 cites W2009263714 @default.
• W2113679439 cites W2014665497 @default.
• W2113679439 cites W2020646973 @default.
• W2113679439 cites W2023606718 @default.
• W2113679439 cites W2028984408 @default.
• W2113679439 cites W2031882974 @default.
• W2113679439 cites W2033571882 @default.
• W2113679439 cites W2041576624 @default.
• W2113679439 cites W2048488747 @default.
• W2113679439 cites W2049409827 @default.
• W2113679439 cites W2053161927 @default.
• W2113679439 cites W2053655408 @default.
• W2113679439 cites W2054602599 @default.
• W2113679439 cites W2056073419 @default.
• W2113679439 cites W2056253789 @default.
• W2113679439 cites W2058429272 @default.
• W2113679439 cites W2069813732 @default.
• W2113679439 cites W2071774615 @default.
• W2113679439 cites W2072565692 @default.
• W2113679439 cites W2079473749 @default.
• W2113679439 cites W2105126729 @default.
• W2113679439 cites W2112059874 @default.
• W2113679439 cites W2112160066 @default.
• W2113679439 cites W2114097850 @default.
• W2113679439 cites W2116385303 @default.
• W2113679439 cites W2118342981 @default.
• W2113679439 cites W2122734862 @default.
• W2113679439 cites W2130216606 @default.
• W2113679439 cites W2133051117 @default.
• W2113679439 cites W2134601446 @default.
• W2113679439 cites W2136091583 @default.
• W2113679439 cites W2152527784 @default.
• W2113679439 cites W2159385264 @default.
• W2113679439 doi "https://doi.org/10.1038/jid.2009.384" @default.
• W2113679439 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3057125" @default.
• W2113679439 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20032992" @default.
• W2113679439 hasPublicationYear "2010" @default.
• W2113679439 type Work @default.
• W2113679439 sameAs 2113679439 @default.
• W2113679439 citedByCount "168" @default.
• W2113679439 countsByYear W21136794392012 @default.
• W2113679439 countsByYear W21136794392013 @default.
• W2113679439 countsByYear W21136794392014 @default.
• W2113679439 countsByYear W21136794392015 @default.
• W2113679439 countsByYear W21136794392016 @default.
• W2113679439 countsByYear W21136794392017 @default.
• W2113679439 countsByYear W21136794392018 @default.
• W2113679439 countsByYear W21136794392019 @default.
• W2113679439 countsByYear W21136794392020 @default.
• W2113679439 countsByYear W21136794392021 @default.
• W2113679439 countsByYear W21136794392022 @default.
• W2113679439 countsByYear W21136794392023 @default.
• W2113679439 crossrefType "journal-article" @default.
• W2113679439 hasAuthorship W2113679439A5007042386 @default.
• W2113679439 hasAuthorship W2113679439A5040150010 @default.
• W2113679439 hasAuthorship W2113679439A5041604568 @default.
• W2113679439 hasAuthorship W2113679439A5042304008 @default.
• W2113679439 hasAuthorship W2113679439A5057337678 @default.
• W2113679439 hasAuthorship W2113679439A5083005519 @default.
• W2113679439 hasBestOaLocation W21136794391 @default.
• W2113679439 hasConcept C104317684 @default.
• W2113679439 hasConcept C127561419 @default.
• W2113679439 hasConcept C129437159 @default.
• W2113679439 hasConcept C136449434 @default.
• W2113679439 hasConcept C170493617 @default.
• W2113679439 hasConcept C185592680 @default.
• W2113679439 hasConcept C2777379352 @default.
• W2113679439 hasConcept C2777459323 @default.
• W2113679439 hasConcept C2779828298 @default.

• next